Protagonist Q3 2022 Earnings Report
Key Takeaways
Protagonist Therapeutics reported its Q3 2022 financial results, highlighting the continued execution of the Phase 3 VERIFY study of rusfertide in polycythemia vera and the appointment of Arturo Molina as Chief Medical Officer.
Continued execution of Phase 3 VERIFY study of rusfertide in polycythemia vera
Arturo Molina, M.D., M.S. named Chief Medical Officer
Three rusfertide poster presentations to be shared at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH) in December
PN-235 (JNJ-77242113), is currently in multiple Phase 2 clinical studies to assess safety and efficacy in moderate-to-severe plaque psoriasis.
Protagonist
Protagonist
Forward Guidance
Protagonist expects the first half of 2023 to be a period of potential transformational value creation for Protagonist.